Detecting glycan cancer biomarkers in serum samples using MALDI FT-ICR mass spectrometry data
Detecting glycan cancer biomarkers in serum samples using MALDI FT-ICR mass spectrometry data
复制标题
DOI：
10.1093/bioinformatics/btn610
复制
发表时间：
2009-01-15
期刊：
影响因子：
5.8
通讯作者：
Rocke, David M.
中科院分区：
文献类型：
--
作者：
Barkauskas, Donald A.;An, Hyun Joo;Rocke, David M.
动机：开发更好的测试来在早期阶段检测癌症是医学界最受追捧的目标之一。尤其重要的是仅需要血液或尿液样本的微创测试。由亲。通过从肿瘤细胞释放到血流中的糖基化蛋白质中裂解低聚糖，我们希望确定聚糖谱，这将有助于通过简单的血液测试来识别癌症患者。本文中的数据是使用基质辅助激光解吸/电离傅里叶变换离子回旋共振质谱 (MALDI FT-ICR MS) 生成的。我们开发了分析此类质谱数据的新方法，并将其应用于来自三种不同类型癌症（乳腺癌、卵巢癌和前列腺癌）的八个数据集。结果：我们开发的技术似乎在 MALDI FT-ICR MS 数据分析中有效。我们在所有八个数据集中发现对照组和癌症组之间存在显着差异，其中包括两种结构相关的化合物，在所研究的所有三种类型的癌症中，对照组和癌症组之间发现它们存在显着差异。
Motivation: The development of better tests to detect cancer in its earliest stages is one of the most sought-after goals in medicine. Especially important are minimally invasive tests that require only blood or urine samples. By pro. ling oligosaccharides cleaved from glycosylated proteins shed by tumor cells into the blood stream, we hope to determine glycan profiles that will help identify cancer patients using a simple blood test. The data in this article were generated using matrix-assisted laser desorption/ionization Fourier transform ion cyclotron resonance mass spectrometry (MALDI FT-ICR MS). We have developed novel methods for analyzing this type of mass spectrometry data and applied it to eight datasets from three different types of cancer (breast, ovarian and prostate).Results: The techniques we have developed appear to be effective in the analysis of MALDI FT-ICR MS data. We found significant differences between control and cancer groups in all eight datasets, including two structurally related compounds that were found to be significantly different between control and cancer groups in all three types of cancer studied.